-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27

Benzinga·08/07/2026 13:46:58
Listen to the news
Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $29 to $27.